As of June 16, 2025, Vistagen Therapeutics Inc (VTGN) reports a Net Margin of -2759.59%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Historical Trend of Vistagen Therapeutics Inc's Net Margin
Over recent years, Vistagen Therapeutics Inc's Net Margin has shown significant volatility. The table below summarizes the historical values:
| Date | Net Margin |
|---|---|
| 2024-03-31 | -2759.59% |
| 2023-03-31 | 25760.87% |
| 2022-03-31 | -4302.70% |
| 2021-03-31 | -1644.95% |
| 2020-03-31 | -820.80% |
This gradual decrease highlights how Vistagen Therapeutics Inc manages its overall profitability and cost control over time.
Comparing Vistagen Therapeutics Inc's Net Margin to Peers
To better understand Vistagen Therapeutics Inc's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| Vistagen Therapeutics Inc (VTGN) | -2759.59% |
| Regeneron Pharmaceuticals Inc (REGN) | 31.07% |
| Amgen Inc (AMGN) | 12.24% |
| Abbvie Inc (ABBV) | 7.59% |
| Gilead Sciences Inc (GILD) | 1.67% |
| Vertex Pharmaceuticals Inc (VRTX) | -4.86% |
Compared to its competitors, Vistagen Therapeutics Inc's Net Margin is about average compared to peers, reflecting typical industry profitability.